

1 **Tuberculosis presentation and outcomes in elderly Hispanics from Tamaulipas, Mexico**

2

3 Belinda A. Medrano¹, Miryoung Lee¹, Gretchen Gemeinhardt², Javier E. Rodríguez-Herrera³,

4 Moncerrato García-Viveros³, Blanca I. Restrepo^{1,4,5,*}

5

6 ¹ Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public

7 Health, University of Texas Health Science Center at Houston, Brownsville campus,

8 Brownsville, TX, USA

9 ² Department of Management, Policy and Community Health, School of Public Health,

10 University of Texas Health Science Center at Houston, Houston, TX, USA

11 ³ Secretaría de Salud de Tamaulipas, Reynosa 88630, Matamoros 87370 and Ciudad Victoria,

12 Tamaulipas, México

13 ⁴ Population Health Program, Texas Biomedical Research Institute, San Antonio, TX, USA

14 ⁵ School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio

15 Grande Valley, Edinburg, TX, USA

16

17 * Corresponding author: 1214 W. Schunior, UTRGV-EREBL Bldg, Edinburg, TX 78541

18 Blanca.i.restrepo@uth.tmc.edu; Tel.: +01-956-279-3841

19

20 **Running title:** Tuberculosis treatment outcomes in elderly Hispanics

21

22

23

24 **Abstract**

25 Old people are at high risk of developing and dying from pulmonary infections like tuberculosis
26 (TB), but there are few studies and particularly in Hispanics. To address these gaps, we sought to
27 identify host factors associated with TB and adverse treatment outcomes in old Hispanics by
28 conducting a secondary analysis of TB surveillance data from Tamaulipas, Mexico (2006-2013;
29 n=8,381). Multivariable logistic regressions were assessed for the elderly (ELD, ≥ 65 years)
30 when compared to young (YA, 18 to 39 years) and middle-aged adults (MAA, 40 to 64 years).
31 We found that the ELD had features associated with a less complicated TB (e.g. less extra-
32 pulmonary TB, abandoning of treatment or having drug resistant TB), and yet, were more likely
33 to die during TB treatment (adj-OR 3.9, 95% CI 2.5, 5.25). Among the elderly, excess alcohol use
34 and low BMI increased their odds of death, while diabetes and BCG vaccination were protective.
35 These data suggest that old people share some, but not all the risk factors for adverse TB
36 treatment outcomes, when compared with younger adults. Furthermore, even though old age in
37 itself is an important predictor of death during TB, the elderly are not prioritized by the World
38 Health Organization for latent TB infection screening and treatment during contact
39 investigations. We propose the inclusion of the elderly as a high-risk group in TB management
40 guidelines.

41

42 **Keywords:** tuberculosis, Hispanics, older people, elderly, gerontology, diabetes, BCG, BMI,
43 treatment outcomes

44 **Introduction**

45 *Mycobacterium tuberculosis* is a bacterial disease that has infected a quarter of the world's
46 population with non-symptomatic latent infection or progressed to active tuberculosis (TB)
47 disease. In 2020, an estimated 9.9 million people developed TB and 1.5 million died [1]. Latent
48 TB infection and active TB disease are more prevalent in the elderly, i.e., adults over the age of
49 65 [2-4]. This is relevant as the global elderly population grows from 1 out of 11 in 2019 to 1 in
50 6 by 2050 [5]. The World Health Organization (WHO) regions of the Eastern Mediterranean,
51 South-East Asia, and Western Pacific already have a significant burden of TB cases in the
52 elderly populations with Taiwan anticipating almost 80% of their new TB cases in the elderly by
53 2035 [2, 6].

54 The elderly face additional risks of TB reactivation and infection compared to younger adults,
55 such as compromised immunity, comorbid conditions, and increased TB exposures due to
56 clustering in nursing homes [7-9]. TB and general mortality are highest in the elderly group [2,
57 10]. An aging population, longer life expectancy, and reactivation of TB disease in the elderly
58 pose challenges to meeting the World Health Organization's 'End TB Strategy' goals of a 90%
59 and 95% reduction in TB incidence and deaths, respectively, by 2035 [1, 8, 10, 11].

60 Despite their high vulnerability, TB in the elderly is understudied, and the available literature is
61 mostly from Asian populations, with few in Hispanics [12-14]. Studies in Latin American
62 Hispanics are warranted given that risk factors for TB such as poverty, migration, homelessness,
63 incarceration, and diabetes have increased in the last decade [15, 16]. Even in a high-income
64 country like the United States, the TB case rate is nine times higher for Hispanics than for non-
65 Hispanic whites (Centers for Disease Control and Prevention [17]).

66 Given the impact of old age on TB elimination efforts, it is important to study the elderly TB
67 group with the goals of improving patient outcomes and preventing additional TB cases. To
68 address this knowledge gap, and particularly among Hispanics, we aimed to identify
69 sociodemographic and medical risk factors and secular trends for TB in the elderly from the state
70 of Tamaulipas in northeastern Mexico. We also sought to identify the risk factors associated with
71 adverse treatment TB outcomes in old age.

72 **Materials and Methods**

73 **Study Population**

74 We conducted a secondary analysis of existing TB surveillance data on adults ages 18 to 99
75 years with a new TB diagnosis and who were reported to the state of Tamaulipas, Mexico
76 between 2006 and 2013. The state's TB program surveillance dataset was described previously
77 [18]. Briefly, the Tamaulipas's TB surveillance dataset was comprised of 12,748 TB patients
78 enrolled between 2005 and 2013, and we excluded repeat episodes from the same subject
79 (n=1,827), individuals less than 18 years old (n=624), recurring TB cases (n=777), and
80 individuals enrolled in 2005 who had poor data quality (n=1,089). This left 8,431 new adult TB
81 patients [18]. For this study, we further excluded 43 individuals identified as having a previous
82 TB episode and seven with missing data on TB treatment outcomes, for a final sample size of
83 8,381 TB patients. Patient data was deidentified and the protocol was approved from the Internal
84 Review Board from UTHHealth Houston (HSC-SPH-15-0489) and the Secretaría de Salud de
85 Tamaulipas (076/2015/CEI).

86 **Participant Characteristics**

87 We compared the elderly group (65 yrs. or older, ELD) to young adults (18-39 yrs., YA) or
88 middle-aged adults (40-64 yrs., MAA). Sociodemographic variables included age, sex,
89 education, Bacille Calmette-Guerin (BCG) vaccination at birth based on the presence of a BCG
90 scar, self-reported excess alcohol use or intravenous (IV) drug use, and low body mass index
91 (BMI <18.5 kg/m² at the time of TB diagnosis). Comorbidities included chronic obstructive
92 pulmonary disease (COPD), self-reported diabetes, and self-reported or laboratory-confirmed
93 HIV. Variables related to TB at the time of diagnosis included disease location (extrapulmonary
94 or pulmonary), positive acid-fast bacilli (AFB) on sputum smears, diagnosis method [culture
95 confirmation by isolation of *M. tuberculosis*, positive AFB smears only, or in their absence, a
96 combination of clinical, epidemiological, radiological and/or histopathological findings], and the
97 number of close contacts. In Mexico, drug susceptibility testing is limited to patients with high
98 suspicion of drug-resistant TB with results available for isoniazid (INH), rifampin (RIF),
99 pyrazinamide (PZA), streptomycin (STR), and ethambutol (EMB). *Mycobacterium tuberculosis*
100 was classified as drug resistant (DR-TB) if resistant to any of the five TB drugs and multi-drug
101 resistant (MDR-TB) when at least INH and RIF were resistant. The adverse outcomes of interest
102 included TB treatment failure (positive AFB smears after five months of TB treatment),
103 abandoned treatment (lost during follow-up for more than three months), and death due to any
104 cause during TB treatment.

105 **Statistical Analyses**

106 Two-group comparisons of binary variables were analyzed by Pearson's chi-square or Fisher's
107 exact test and the Student's-t test was used for mean comparisons between two groups.
108 Increasing or decreasing trends across age groups or across time were established by the score
109 test for the trend of odds for binary variables. To conduct comparisons between-group, trends

110 across age groups, and trends across time for polytomous and numerical variables, we used the
111 nptrend command in STATA, which is a nonparametric test for trends across ordered groups (an
112 extension of the Wilcoxon rank-sum test). For multiple logistic regressions models, we used
113 backward selection with consideration of variables with p values less than 0.20 in bivariable
114 analysis, and keeping age and sex as key sociodemographics in final models. Effect
115 modification variables for age and each predictor variable were included in simple logistic
116 regression models for adverse outcomes, to determine if age modifies the observed effect of each
117 predictor variable. Statistical significance was set at Type I error (alpha) level <0.05. Data
118 analysis was performed using STATA IC (Stata Corp LLC, College Station, TX) 14.

119 **Results**

120 **Sociodemographics and Comorbidities in the Elderly**

121 The characteristics of the 8,381 TB patients for analysis are described in **Table 1**. Their mean
122 age was 43 years (SD 16.6; range 18 to 97). Males comprised 65.5% of all TB patients. Less than
123 half (42.2%) had a high school degree or higher education, three-fourths (76.2%) had a history of
124 BCG vaccination, 5.6% reported excess alcohol use, 0.5% were IV drug users, and 8.3% had low
125 BMI. The most prevalent comorbidity was diabetes (25.2%), followed by HIV (5.3%) and
126 COPD (0.9%).

127 The distribution of TB patients by age group was: 46% in YA, 42% in MAA, and 12% in ELD.
128 Mean ages for YA, MAA, and ELD TB patient groups were 28 (SD 6.2), 50 (SD 6.9), and 73
129 (SD 6.5) years, respectively. The ELD differed from the two younger age groups in their lower
130 level of education (high school degree or higher in 10.9% in ELD vs 56.9% in YA or 35.5% in
131 MAA), BCG vaccination (48.8% in ELD vs 83.6% in YA and 75.7% in MAA), and IV drug use

132 (0.1% in ELD vs 0.8% in YA). Accordingly, significant trends with older age (from YA to MAA
133 to ELD) included a decrease in education level, BCG vaccination rates, and IV drug use, trend p
134 <0.001 for all. Low BMI was highest in the ELD (10.3%) followed by YA (9.3%) and MAA
135 (6.6%).

136 For comorbidities, COPD was more common among the ELD (4.1% in ELD vs 0.1% in YA and
137 0.7% in MAA; $p <0.001$ for increasing trend with older age). Diabetes increased with older age
138 (trend $p <0.001$), although MAA had the highest prevalence (40%), with the ELD having 31.9%
139 and YA 10% ($p <0.001$). HIV prevalence was lowest in the ELD (0.5% in ELD vs 7.7% YA and
140 4.0% in MAA; $p <0.001$ for decreasing trend with older age).

141 **TB-related Characteristics**

142 Most patients had pulmonary TB (92%) and a positive AFB smear at the time of diagnosis
143 (85.1%; **Table 1**). Cultures are not routinely performed in Tamaulipas, and hence, the diagnosis
144 was mostly based on smear results (79.1%), with only 6.8% being culture-confirmed. Each TB
145 patient had an average of 3.7 close contacts. When compared to YA, the ELD had less extra-
146 pulmonary TB (ELD 6.0% vs YA 9.4%; decreasing trend $p <0.001$) or culture-confirmed TB
147 (ELD 5.5% vs YA 8.0%). The ELD had the highest mean number of close contacts (ELD 4.1 vs
148 3.7 in YA or 3.6 in MAA).

149 **TB Drug Resistance**

150 Drug susceptibility testing was only available for 1,165 (13.9%) TB patients, with more testing
151 in YA (15.4%) and MAA (14.2%) vs. the ELD (7.3%; trend $p <0.001$; **Table 2**). For primary
152 analysis, we assumed that the absence of susceptibility results indicated drug-susceptible TB

153 since testing is prompted when DR-TB is suspected (**Table 2**). We found that DR-TB decreased
154 with age (trend $p=0.030$). Among all age groups, the highest monoresistance was for INH
155 (1.2%), and across age groups, only INH monoresistance showed a decreasing trend with age
156 ($p=0.002$). MDR-TB occurred in 0.6% of all patients and did not differ across age groups.
157 Similar analysis but limited to isolates tested for drug resistance provided similar findings (**S1**
158 **Table**).

159 **Adverse TB Treatment Outcomes**

160 Among all patients, 14.9% had one of the following adverse outcomes: treatment failure (1.9%),
161 abandoned treatment (6.9%), or death (6.2%), **Table 1**. Adverse TB treatment outcomes were
162 highest among the ELD (20.1%) followed by YA (15.4%) and MAA (12.9%) groups. Treatment
163 failure did not differ between age groups, but the ELD group was less likely to abandon
164 treatment (4.3%) when compared to YA (9.2%; $p < 0.001$) with a decreasing trend with older age
165 (trend $p < 0.001$). In contrast, the ELD were more likely to die during TB treatment (13.6%)
166 when compared to YA (4.5%) or MAA (5.8%) with an increasing trend with older age (trend p
167 < 0.001).

168 For multivariable analysis, we examined whether old age was independently associated with
169 adverse TB treatment outcomes with YA as the reference group. IV drug use and HIV were
170 excluded as predictor variables due to their low prevalence in the ELD group (**Table 3**). Age
171 groups were not associated with treatment failure. Instead, among all age groups, adjusted
172 models showed that treatment failure was higher for males, although statistical significance was
173 not reached (adj. OR 1.45, 95% CI 0.99, 2.10), those with positive AFB smears (adj. OR 1.97,
174 95% CI 1.03, 3.79) or DR-TB, (adj. OR 13.85, 95% CI 9.42, 20.37). Higher education was

175 protective against treatment failure (adj. OR 0.69, 95% CI 0.48, 0.99). Abandoning treatment
176 was 59% lower in the elderly (adj. OR 0.41, 95% CI 0.28, 0.59) when compared to YA (**Table**
177 **3**). Among all TB patients, the factors associated with higher odds of abandoning treatment were
178 male sex (adj. OR 2.09, 95% CI 1.65, 2.66), excess alcohol use (adj. OR 1.44, 95% CI 1.03,
179 2.01), and low BMI (adj. OR 1.59, 95% CI 1.18, 2.13). Protective factors against abandoning
180 treatment included high school or higher education (adj. OR 0.74, 95% CI 0.60, 0.90), having
181 extrapulmonary disease (adj. OR 0.51, 95% CI 0.30, 0.87), and positive AFB smear at diagnosis
182 (adj. OR 0.63, 95% CI 0.49, 0.82). The odds of abandoning treatment decreased by 11% (adj.
183 OR 0.89, 95% CI 0.85, 0.93) for each additional close contact reported by a TB patient. Death
184 was four-fold higher with old age (ELD vs YA: adj. OR 3.90, 95% CI 2.90, 5.25; **Table 3**).
185 Among all TB patients, the odds of death were also higher for MAA (adj. OR 1.62, 95% CI 1.25,
186 2.09), males (adj. OR 1.59, 95% CI 1.24, 2.04), excess alcohol users (adj. OR 1.66, 95% CI 1.15,
187 2.39), those with low BMI (adj. OR 2.14, 95% CI 1.60, 2.87), and extrapulmonary disease (adj.
188 OR 1.94, 95% CI 1.29, 2.91). BCG vaccination (adj. OR 0.67, 95% CI 0.53, 0.85), diabetes (adj.
189 OR 0.59, 95% CI 0.44, 0.78), and positive AFB smear (adj. OR 0.63, 95% CI 0.47, 0.84) were
190 protective against death.

191 We sought to identify independent predictors of adverse outcomes among the ELD group alone
192 (**S2 Table**). In the ELD, the odds of treatment failure was 14 times higher in patients with DR-
193 TB (adj. OR 14.10, 95% CI 4.69, 42.32). Abandoning treatment decreased by 56% for those with
194 a positive AFB smear and by 15% for each close contact. The odds of death increased by 4% for
195 each additional year of life, and by more than 2-fold in those with excess alcohol use or low
196 BMI. Male sex was not associated with any adverse outcome in the ELD (**S2 Table**), despite its
197 relationship with treatment failure, abandoning treatment and death in all age groups (**Table 3**).

198 Finally, we evaluated if among all TB patients, age would modify the associations between host
199 factors and adverse TB treatment outcomes. However, multivariable models with additional
200 interaction terms for age did not show significant associations (**S3 Table**).

201 **Trends Over the Eight-year Period in the ELD**

202 We evaluated if there were trends over time (2006 -- 2013) in the prevalence or characteristics of
203 the ELD group. Among all TB patients, the proportion of ELD remained similar across the years
204 (range 11.2 – 13.8%; p 0.531; **S4 Table**). Among the ELD group only, there was an increasing
205 trend in education level (p <0.001), BCG vaccination (p <0.001), diabetes (p 0.010),
206 extrapulmonary TB (p 0.005) and DR-TB (p 0.002; **Tables 4 and S4**). We also evaluated trends
207 over time for younger adults (**Table 4**) and found that unlike the ELD, the YA and MAA had a
208 reduction in excess alcohol use, low BMI, and abandoning of TB treatment, and that the YA had
209 a decreasing trend in death.

210 **Discussion**

211 Despite projections showing a worldwide increase in the proportion of older individuals, studies
212 in the elderly are underrepresented when compared to those in younger adults [19-21]. This
213 knowledge gap extends to the elderly with TB, especially in the Americas. To address this
214 disparity, we sought to obtain a better understanding of elderly Hispanics with TB using TB
215 surveillance data from the Mexican state of Tamaulipas. The elderly comprised 12.3% of all
216 adult TB patients, and over the eight-year study period we observed: i) an improvement in
217 factors that could be protective for TB (e.g. higher education and BCG vaccination coverage), ii)
218 an increase in factors that favor adverse TB outcomes (e.g. extrapulmonary TB and DR-TB), and

219 iii) an increase in diabetes, which had a protective effect on TB outcomes in our ELD cohort as
220 discussed below [22-26]. The elderly differed from younger adults in their higher prevalence of
221 COPD, which could increase their odds of a more severe TB disease, and in having less BCG
222 vaccination and lower education level, which have been associated with higher odds of TB [14,
223 27, 28]. However, old age was also associated with factors known to improve their TB prognoses
224 such as less IV drug use, HIV, and extra-pulmonary TB, and abandonment of treatment [29-31].
225 The distribution of risk factors for TB, therefore, can have variations across all adult age groups
226 and identifying the high-risk profiles in the elderly is important for prompt TB suspicion,
227 diagnosis, and treatment initiation, in order to improve their prognosis.

228 Regardless of a combination of risk and protective factors for TB in the elderly in multivariable
229 models, the highest threat to this age group was their higher odds of death. This finding is
230 consistent with previous studies in the elderly, and we now report it in our Hispanic TB patients
231 [9, 32]. And among the elderly with TB, death was associated with an increase in age, excess
232 alcohol use and low BMI. These factors also contribute to the higher odds of death in all adult
233 age groups [1, 2, 25, 33, 34]. In contrast, male sex was a risk factor for death in YA and MAA
234 TB patients, but not in the ELD in our study.

235 The prevalence of type 2 diabetes increases with age, as observed in our TB cohort [35, 36].
236 Diabetes is a risk for TB in adults, this includes findings using prospective or retrospective
237 cohorts from Hispanics in US and Mexican communities [18, 37, 38] but not in older people [13,
238 14]. We posit that differences between diabetes in younger versus older adults may be explained
239 by differences in the pathophysiology and/or the management of type 2 diabetes [13]. While
240 diabetes in the elderly may not be a risk factor for TB development, in the present study, we
241 evaluated if it would be associated with higher odds of death. We found the opposite, with

242 diabetes being protective, as reported in Brazil by [39]. A higher risk of adverse TB treatment
243 outcomes in the presence of diabetes has been reported in previous studies, although not
244 specifically evaluated in older patients [9, 25, 40]. A possible explanation for these discrepant
245 findings may be the higher prevalence of obesity in diabetes patients. While diabetes is a risk
246 factor for TB, obesity is protective against TB [41, 42]. It is possible that the higher prevalence
247 of obesity in our study population offsets, to some extent, the risk of death during TB that is
248 conferred by diabetes [43]. Consistent with this finding, a study in adults from India reported that
249 diabetes offsets the risk of adverse outcomes conferred by low BMI [44]. Further studies are
250 needed to understand the relationship between diabetes, BMI, death in TB patients, and old age.

251 We found that BCG vaccination at birth decreased with older age. This is consistent with the
252 lower prevalence of BCG vaccination in the elderly versus younger adults with TB in a
253 prospective research cohort [14]. In that study, BCG vaccination at birth was associated with
254 lower odds of TB, but only in the elderly. This finding was intriguing given that BCG is known
255 to protect infants and young children from TB, but not adults [1]. Here we find that BCG
256 vaccination at birth is associated with lower odds of death from TB in all age groups. Our
257 findings are consistent with the association between unfavorable TB treatment outcomes and
258 absence of a BCG scar in a Malaysian population [25]. Together, these findings suggest a
259 possible protective role of BCG with respect to TB risk or death, although further studies are
260 needed to rule out confounding factors that were not available in the surveillance dataset, such as
261 lower access to healthcare in non-BCG-vaccinated individuals. At the cellular level, BCG
262 vaccination induces epigenetic changes in innate immune cells (e.g., trained immunity) that
263 associate with protection against TB and other microbial infections [45]. Thus, basic science

264 studies are also warranted to help elucidate how BCG vaccination at birth may contribute to TB
265 protection and lower the risk of death in the elderly.

266 We found a decreasing prevalence of extrapulmonary TB with older age, which is consistent
267 with previous studies [31, 46]. These age-related differences may be due to a lower prevalence of
268 comorbidities like HIV, when compared to younger TB patients, that favor extrapulmonary
269 disease [31, 46, 47].

270 Abandonment of treatment contributes to adverse outcomes but we found that the ELD are less
271 likely to abandon TB treatment [30, 48, 49]. Interestingly, we found an inverse association
272 between the number of TB contacts and odds of abandoning treatment in all age groups, or
273 among ELD patients only. Further studies are needed to determine if this finding is consistent
274 with reports indicating that the level and quality of social support received by patients affects
275 their health outcomes and adherence to treatments [50-53].

276 Patients with drug-resistant TB are more likely to have adverse treatment outcomes [1, 49, 54,
277 55]. While we found a lower prevalence of DR-TB in the ELD, our findings point to the
278 importance of identifying these patients given their higher odds of treatment failure.

279 Our large sample size, coverage over an eight-year period, and breakdown of age into three
280 groups, allowed for an in-depth cross-sectional assessment of unique features in ELD TB
281 patients with respect to their sociodemographics, comorbidities, TB characteristics, and
282 treatment outcomes. Limitations included the secondary nature of the data analyses. Diabetes
283 diagnosis and duration of disease, excess alcohol use, and, to some extent, HIV status were self-
284 reported and may be underestimated, although we do not anticipate that there would be a
285 differential underreporting of these host characteristics in the ELD when compared to other age

286 groups. Low BMI was reported as a categorical variable with no further granularity to assess the
287 contribution of different levels of body weight or obesity to TB risk or protection in the elderly.
288 Smoking is a risk factor for TB and known to be more prevalent in older cohorts, but not
289 reported in this surveillance dataset [14]. Finally, DR-TB testing was only evaluated upon
290 suspicion, as in most TB-endemic countries worldwide, and hence, pan-susceptibility was
291 assumed when data was not available. However, analysis limited to patients in whom drug
292 susceptibility was tested provided similar results (**Table S1**).

293 Our study raises awareness of the high vulnerability of older people to death from TB. Per
294 WHO's latent TB infection management guidelines, TB contact investigations focus on the
295 identification of high-risk groups for TB development. However, these are limited to children
296 below 5 years of age or people living with HIV, and of other adults and children household
297 contacts in low TB incidence countries without mention of the growing elderly population [56].
298 Our findings call for the need to consider the elderly in a similar high-risk category. A recent
299 study showed that Interferon-gamma release assays (IGRA) are effective for identification of
300 latent TB infection in the elderly [57]. We also identified modifiable sociodemographic factors
301 associated with higher odds of death during TB in the elderly, such as excess alcohol use or low
302 BMI. Close supervision of elderly with new TB or LTBI should be offered for counseling of
303 alcohol use or nutritional support. We also found that abandoning treatment was more likely
304 when patients have fewer contacts. Hence, protocols to promote social workers at TB clinics to
305 reach out to family members to emphasize the importance of social support, can have a positive
306 impact on treatment success. By studying the elderly TB group separately from the other distinct
307 adult age groups, we will have a better understanding of how to approach the challenges of TB
308 eradication in this understudied and vulnerable population.

309 **Acknowledgements**

310 We thank the personnel from all the sanitary jurisdictions of the Secretaría de Salud de
311 Tamaulipas who contributed to the collection and recording of data from the TB patients, and Dr.
312 Santa Elizabeth Ceballos Liceaga for providing the surveillance datasets for our analysis as
313 coordinator of the Sistema de Vigilancia Epidemiológica de Tuberculosis y Lepra, Dirección
314 General de Epidemiología, Secretaría de Salud de Mexico. We also thank Dr. Bassent Abdelbary
315 for generation of the basic dataset used for analysis and guidance for data analysis.

316

317 **References**

318

319 1. World-Health-Organization. Global tuberculosis report 2021.

320 [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021)

321 [2021](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021) [Internet]. 2021 2022. Available from: [https://www.who.int/teams/global-tuberculosis-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021)

322 [programme/tb-reports/global-tuberculosis-report-2021](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021).

323 2. Caraux-Paz P, et al. Tuberculosis in the Elderly. *J Clin Med*. 2021;10(24).

324 3. Hochberg NS, Horsburgh CR, Jr. Prevention of tuberculosis in older adults in the United

325 States: obstacles and opportunities. *Clin Infect Dis*. 2013;56(9):1240-1247.

326 4. Li T, et al. Age-Specific Pulmonary Tuberculosis Notification Rates - China, 2008-2018.

327 *China CDC Wkly*. 2022;4(38):841-846.

328 5. World population aging 2019. New York, NY, USA: United Nations, 2020 2020. Report

329 No. Available from:

330 [https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationA](https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf)

331 [geing2019-Report.pdf](https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf).

332 6. Ku CC, Dodd PJ. Forecasting the impact of population ageing on tuberculosis incidence.

333 *PLoS One*. 2019;14(9):e0222937.

334 7. Chitnis AS, et al. Trends in Tuberculosis Cases Among Nursing Home Residents,

335 California, 2000 to 2009. *J Am Geriatr Soc*. 2015;63(6):1098-1104.

- 336 8. Murali S, et al. Comparison of profile and treatment outcomes between elderly and non-
337 elderly tuberculosis patients in Puducherry and Tamil Nadu, South India. PLoS One.
338 2021;16(8):e0256773.
- 339 9. Negin J, et al. Tuberculosis among older adults--time to take notice. Int J Infect Dis.
340 2015;32:135-137.
- 341 10. Di Gennaro F, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016-2019
342 Retrospective Analysis from an Italian Referral Hospital. Antibiotics (Basel). 2020;9(8).
- 343 11. Cheng J, et al. Incidence and risk factors of tuberculosis among the elderly population in
344 China: a prospective cohort study. Infect Dis Poverty. 2020;9(1):13.
- 345 12. Garcia-Goez JF, et al. Tuberculosis in elderly patients in the city of Cali, Colombia: a
346 hospital-based cohort study. J Bras Pneumol. 2020;46(5):e20200072.
- 347 13. Restrepo BI, et al. Differential Role of Type 2 Diabetes as a Risk Factor for Tuberculosis
348 in the Elderly versus Younger Adults. Pathogens. 2022;11(12).
- 349 14. Scordo JM, et al. A prospective cross-sectional study of tuberculosis in elderly Hispanics
350 reveals that BCG vaccination at birth is protective whereas diabetes is not a risk factor. PLoS
351 One. 2021;16(7):e0255194.
- 352 15. Tuberculosis in the Americas. Regional Report 2020. Washington D.C: Pan American
353 Health Organization (PAHO), 2021 2021. Report No. Available from:
354 <https://iris.paho.org/handle/10665.2/55194>.

- 355 16. Ranzani OT, et al. Increasing tuberculosis burden in Latin America: an alarming trend for
356 global control efforts. *BMJ Glob Health*. 2021;6(3).
- 357 17. CDC. TB and Hispanic or Latino Persons. Centers for Disease Control and Prevention,
358 2022 11/22/2022. Report No. Available from:
359 <https://www.cdc.gov/tb/topic/populations/latino/default.htm>.
- 360 18. Abdelbary BE, et al. Tuberculosis-diabetes epidemiology in the border and non-border
361 regions of Tamaulipas, Mexico. *Tuberculosis (Edinb)*. 2016;101S:S124-S134.
- 362 19. Mody L, et al. Recruitment and retention of older adults in aging research. *J Am Geriatr*
363 *Soc*. 2008;56(12):2340-2348.
- 364 20. World population aging 2020 Highlights. New York: United Nations, 2020 2020. Report
365 No. Available from:
366 [https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/docu](https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Nov/undes_a_pd-2020_world_population_ageing_highlights.pdf)
367 [ments/2020/Nov/undes_a_pd-2020_world_population_ageing_highlights.pdf](https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Nov/undes_a_pd-2020_world_population_ageing_highlights.pdf).
- 368 21. World-Health-Organization. Ageing and health. World Health Organization; WHO, 2022
369 10/1/2022. Report No. Available from: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)
370 [sheets/detail/ageing-and-health](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health).
- 371 22. Atif M, et al. Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur,
372 Pakistan; a record review. *J Pharm Policy Pract*. 2020;13:35.

- 373 23. Gebrezgabiher G, et al. Treatment Outcome of Tuberculosis Patients under Directly
374 Observed Treatment Short Course and Factors Affecting Outcome in Southern Ethiopia: A Five-
375 Year Retrospective Study. PLoS One. 2016;11(2):e0150560.
- 376 24. Koch A, et al. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and
377 treatment. Curr Opin Pharmacol. 2018;42:7-15.
- 378 25. Tok PSK, et al. Determinants of unsuccessful treatment outcomes and mortality among
379 tuberculosis patients in Malaysia: A registry-based cohort study. PLoS One.
380 2020;15(4):e0231986.
- 381 26. Yen YF, et al. Determinants of mortality in elderly patients with tuberculosis: a
382 population-based follow-up study. Epidemiol Infect. 2017;145(7):1374-1381.
- 383 27. Jain VK, et al. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr.
384 2020;14(5):1439-1443.
- 385 28. Nordholm AC, et al. Social determinants of tuberculosis: a nationwide case-control study,
386 Denmark, 1990-2018. Int J Epidemiol. 2022;51(5):1446-1456.
- 387 29. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility
388 to and development of tuberculosis. Epidemiol Rev. 2001;23(2):288-301.
- 389 30. Mansour G, et al. Factors Related to Non-Adherence and Abandonment of Pulmonary
390 Tuberculosis Treatment. Medicina (Ribeirao Preto). 2021;54(2):e-172543.

- 391 31. Qian X, et al. Risk factors for extrapulmonary dissemination of tuberculosis and
392 associated mortality during treatment for extrapulmonary tuberculosis. *Emerg Microbes Infect.*
393 2018;7(1):102.
- 394 32. Leung EC, et al. Delayed diagnosis of tuberculosis: risk factors and effect on mortality
395 among older adults in Hong Kong. *Hong Kong Med J.* 2018;24(4):361-368.
- 396 33. Rehm J, et al. The association between alcohol use, alcohol use disorders and
397 tuberculosis (TB). A systematic review. *BMC Public Health.* 2009;9:450.
- 398 34. Volkmann T, et al. Tuberculosis and excess alcohol use in the United States, 1997-2012.
399 *Int J Tuberc Lung Dis.* 2015;19(1):111-119.
- 400 35. CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the
401 United States. Atlanta, GA, USA: Centers for Disease Control and Prevention, 2022 6/29/2022.
402 Report No. Available from: <https://www.cdc.gov/diabetes/data/statistics-report/index.html>.
- 403 36. Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. *Prz Menopauzalny.*
404 2017;16(2):38-43.
- 405 37. Al-Rifai RH, et al. Association between diabetes mellitus and active tuberculosis: A
406 systematic review and meta-analysis. *PLoS One.* 2017;12(11):e0187967.
- 407 38. Restrepo BI, et al. Cross-sectional assessment reveals high diabetes prevalence among
408 newly-diagnosed tuberculosis cases. *Bull WHO.* 2011;89(5):352-359.

- 409 39. Evangelista M, et al. Tuberculosis associated with diabetes mellitus by age group in
410 Brazil: a retrospective cohort study, 2007-2014. *Braz J Infect Dis.* 2020;24(2):130-136.
- 411 40. Reed GW, et al. Impact of diabetes and smoking on mortality in tuberculosis. *PLoS ONE.*
412 2013;8(2):e58044.
- 413 41. Harries AD. Having diabetes and being underweight in Asia: a potent risk factor for
414 tuberculosis. *Int J Tuberc Lung Dis.* 2019;23(12):1237-1238.
- 415 42. Lin HH, et al. Association of Obesity, Diabetes, and Risk of Tuberculosis: Two
416 Population-Based Cohorts. *Clin Infect Dis.* 2018;66(5):699-705.
- 417 43. Restrepo BI, et al. Diabetes screen during tuberculosis contact investigations highlights
418 opportunity for diabetes diagnosis and reveals metabolic differences between ethnic groups.
419 *Tuberculosis (Edinb).* 2018;113:10-18.
- 420 44. Kornfeld H, et al. Impact of Diabetes and Low Body Mass Index on Tuberculosis
421 Treatment Outcomes. *Clin Infect Dis.* 2020;71(9):e392-e398.
- 422 45. Netea MG, et al. Defining trained immunity and its role in health and disease. *Nat Rev*
423 *Immunol.* 2020;20(6):375-388.
- 424 46. Pang Y, et al. Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China,
425 2008-2017. *Emerg Infect Dis.* 2019;25(3):457-464.

- 426 47. Shivakoti R, et al. Association of HIV infection with extrapulmonary tuberculosis: a
427 systematic review. *Infection*. 2017;45(1):11-21.
- 428 48. CDC. Basic TB facts. Atlanta, GA, USA: Centers for Disease Control and Prevention,
429 Division of Tuberculosis Elimination NCfH, Viral Hepatitis, STD, and TB Prevention; 2016
430 03/20/2016. Report No. Available from: <https://www.cdc.gov/tb/topic/basics/default.htm>.
- 431 49. Trebucq A, et al. Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade
432 of Evidence. *J Clin Med*. 2019;9(1).
- 433 50. Boen CE, et al. Social Relationships, Inflammation, and Cancer Survival. *Cancer*
434 *Epidemiol Biomarkers Prev*. 2018;27(5):541-549.
- 435 51. Cayla JA, et al. Tuberculosis treatment adherence and fatality in Spain. *Respir Res*.
436 2009;10(1):121.
- 437 52. Li X, et al. Effectiveness of comprehensive social support interventions among elderly
438 patients with tuberculosis in communities in China: a community-based trial. *J Epidemiol*
439 *Community Health*. 2018;72(5):369-375.
- 440 53. World-Health-Organization. Adherence to long-term therapies : evidence for action.
441 World Health Organization; WHO, 2003 2003. Report No. Available from:
442 <https://apps.who.int/iris/handle/10665/42682>.

443 54. Abdelbary BE, et al. Predicting treatment failure, death and drug resistance using a
444 computed risk score among newly diagnosed TB patients in Tamaulipas, Mexico. *Epidemiol
445 Infect.* 2017;145(14):3020-3034.

446 55. Giri VP, et al. The Characteristics and Patterns of Drug-Resistant Pulmonary
447 Tuberculosis in Eastern India. *Trop Med Infect Dis.* 2022;7(9).

448 56. World-Health-Organization. Latent tuberculosis infection: updated and consolidated
449 guidelines for programmatic management. World Health Organization; WHO, 2018 2018.
450 Report No. Available from: <https://apps.who.int/iris/handle/10665/260233>.

451 57. Scordo JM, et al. Interferon Gamma Release Assays for Detection of Latent
452 Mycobacterium tuberculosis in Elderly Hispanics. *Int J Infect Dis.* 2021.

453

454

455

456 **Supporting Information**

457 **S1 Table. TB drugs susceptibility sub-analysis that excludes not tested and unknown from**
458 **drug resistance calculations.**

459 **S2 Table. Multivariable analyses for predicting treatment failure, abandoned treatment,**
460 **and death in the elderly (ELD) group.**

461 **S3 Table. Evaluation of age as an effect modifier of the association between the predictor**
462 **variables listed and adverse TB outcomes.**

463 **S4 Table. Trends over time (2006 – 2013) in the prevalence of the Elderly group or their**
464 **characteristics.**

Table 1. Descriptive Characteristics of TB Patients by Age Group, Tamaulipas 2006 - 2013

	All Adults	YA	MAA	ELD	ELD vs.	ELD vs.	Trend Across
	(≥ 18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	YA	MAA	Age Groups^a
Total n (row %)	8381 (100)	3854 (46.0)	3492 (41.7)	1035 (12.3)	p-value ^a	p-value ^a	p-value ^{b, †}
Sociodemographic Characteristics							
Age	43 (16.6)	28 (6.2)	50 (6.9)	73 (6.5)			
Male Sex	5493 (65.5)	2554 (66.3)	2287 (65.5)	652 (63.0)	0.049	0.139	0.068
High School or Higher (n=8040)	3395 (42.2)	2093 (56.9)	1194 (35.5)	108 (10.9)	<0.001	<0.001	↓ <0.001
BCG Vaccination (n=7814)	5955 (76.2)	3052 (83.6)	2453 (75.7)	450 (48.8)	<0.001	<0.001	↓ <0.001
Excess Alcohol	473 (5.6)	198 (5.1)	236 (6.8)	39 (3.8)	0.069	<0.001	0.995
IV Drug Use	39 (0.5)	30 (0.8)	8 (0.2)	1 (0.1)	0.013	0.694	↓ <0.001
Low BMI	696 (8.3)	360 (9.3)	229 (6.6)	107 (10.3)	0.333	<0.001	0.275
Comorbidities							
COPD	72 (0.9)	5 (0.1)	25 (0.7)	42 (4.1)	<0.001	<0.001	↑ <0.001
Diabetes	2111 (25.2)	386 (10.0)	1395 (40.0)	330 (31.9)	<0.001	<0.001	↑ <0.001
HIV	442 (5.3)	297 (7.7)	140 (4.0)	5 (0.5)	<0.001	<0.001	↓ <0.001
TB-related Characteristics							
TB Location (n=8380)							

Extrapulmonary TB	670 (8.0)	362 (9.4)	246 (7.0)	62 (6.0)	0.001	0.237	↓ <0.001
Pulmonary TB	7710 (92.0)	3491 (90.6)	3246 (93.0)	973 (94.0)			
Positive AFB Smear (n=7683)	6537 (85.1)	2934 (83.7)	2781 (86.1)	822 (86.9)	0.016	0.520	↑ 0.002
TB Diagnosis Type							
Culture confirmation	571 (6.8)	308 (8.0)	206 (5.9)	57 (5.5)	0.017	0.195	0.794
AFB Smear only	6631 (79.1)	2957 (76.7)	2841 (81.4)	833 (80.5)			
Clinical-epidemiological ^c	1145 (13.7)	571 (14.8)	436 (12.5)	138 (13.3)			
Missing	34 (0.4)	18 (0.5)	9 (0.3)	7 (0.7)			
No. of Contacts (n=8103)	3.7 (2.6)	3.7 (2.4)	3.6 (2.5)	4.1 (3.1)	<0.001	<0.001	0.220
Adverse treatment Outcomes							
Treatment Failure	156 (1.9)	64 (1.7)	69 (2.0)	23 (2.2)	0.225	0.622	0.176
Abandoned Treatment	579 (6.9)	356 (9.2)	179 (5.1)	44 (4.3)	<0.001	0.253	↓ <0.001
Died	517 (6.2)	172 (4.5)	204 (5.8)	141 (13.6)	<0.001	<0.001	↑ <0.001

Note: Data expressed as number (column %) for categorical variables and mean (standard deviation) for continuous variables and number of Contacts.

Analysis of each variable includes all 8,381 TB patients except when indicated in parenthesis. YA=young adults, MAA=middle-aged adults,

ELD=elderly

^a Chi-square test or Fisher's Exact test for categorical variables and Student t test for continuous variables

^b Score test for trend of odds for categorical variables and the nonparametric test for trend across ordered groups, an extension of the Wilcoxon rank-sum test, was used for comparing the number of contacts across groups

^c Clinical-epidemiological diagnosis is based on signs and symptoms, epidemiology, radiological and/or histological findings

† Trend direction with respect to old age is indicated by arrows preceding the trend p values

Table 2. TB Drug Resistance Prevalence by Age Group

	All Adults	YA	MAA	ELD	Trend across age groups
	(≥ 18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	p-value ^{b,†}
Total n	8381	3854	3492	1035	
Tested	1165 (13.9)	593 (15.4)	496 (14.2)	76 (7.3)	↓ <0.001
DR-TB	257 (3.1)	134 (3.5)	99 (2.8)	24 (2.3)	↓ 0.030
INH	99 (1.2)	57 (1.5)	39 (1.1)	3 (0.3)	↓ 0.002
RIF	6 (0.1)	4 (0.1)	2 (0.1)	0 (0)	0.238
PZA	6 (0.1)	2 (0.1)	3 (0.1)	1 (0.1)	0.544
STR	36 (0.4)	12 (0.3)	17 (0.5)	7 (0.7)	0.083
EMB	4 (0.1)	3 (0.1)	0 (0)	1 (0.1)	0.633
MDR-TB	54 (0.6)	26 (0.7)	22 (0.6)	6 (0.6)	0.715

Note: Data expressed as n (column %). Total n = Total number of TB patients in each age group. This is the denominator for all calculations where those not tested were considered drug-susceptible as described in the text. YA=young adults, MAA=middle-aged adults, ELD=elderly. Tested = susceptibility testing documented. DR-TB= resistant to any of the TB drugs listed. Mono-resistance is listed for individual antibiotics: INH= isoniazid, RIF= rifampin, PZA= pyrazinamide, STR= streptomycin, EMB= ethambutol. MDR-TB=multi-drug resistant TB defined as resistant to at least INH and RIF.

^a Chi-square or Fisher's Exact test

^b Score test for trend of odds across the three age groups

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values

Table 3. Multivariable analyses to identify whether old age (ELD) is an independent predictor of treatment failure, abandoned treatment, or death

Predictor Variables	Treatment Failure		Abandoned Treatment		Died	
	adj. OR	95% CI	adj. OR	95% CI	adj. OR	95% CI
Age Group						
YA (18 - 39 y)	1.00		1.00		1.00	
MAA (40 - 64 y)	1.23	0.85, 1.77	0.49	0.40, 0.61	1.62	1.25, 2.09
ELD (≥ 65 y)	1.39	0.83, 2.33	0.41	0.28, 0.59	3.90	2.90, 5.25
Sociodemographic Characteristics						
Male Sex	1.45	0.99, 2.10	2.09	1.65, 2.66	1.59	1.24, 2.04
High School or Higher	0.69	0.48, 0.99	0.74	0.60, 0.90		
BCG Vaccination					0.67	0.53, 0.85
Excess Alcohol			1.44	1.03, 2.01	1.66	1.15, 2.39
Low BMI			1.59	1.18, 2.13	2.14	1.60, 2.87
Comorbidities						
COPD						
Diabetes					0.59	0.44, 0.78
TB-related Characteristics						
Extrapulmonary TB			0.51	0.30, 0.87	1.94	1.29, 2.91
Positive AFB Smear	1.97	1.03, 3.79	0.63	0.49, 0.82	0.63	0.47, 0.84
No. of Contacts			0.89	0.85, 0.93		
DR-TB	13.85	9.42, 20.37				

Note: Predictor variables with a significance level <0.20 were included in the initial full models. Reduced models (shown) include age group plus predictor variables with a significance level <0.05 . adj. OR=adjusted odds ratio. CI=confidence intervals, YA=young adults, MAA=middle-aged adults, ELD=elderly

Table 4. Trends across time (2006--2013) in sociodemographic and clinical characteristics of TB patients by age groups ^{a, †}

	All Adults (≥ 18 y) 8381 (100%)	YAA (18 - 39 y) 3854 (46.0%)	MAA (40 - 64 y) 3492 (41.7%)	ELD (≥65 y) 1035 (12.3%)
Sociodemographic Characteristics				
Male Sex	↓0.043	0.070	0.218	0.982
High School or Higher Education (n=8040)	↑<0.001	↑<0.001	↑<0.001	↑<0.001
BCG Vaccination (n=7814)	↑<0.001	↑<0.001	↑<0.001	↑0.001
Excess Alcohol	↓<0.001	↓<0.001	↓<0.001	0.168
Low BMI	↓<0.001	↓0.004	↓<0.001	0.158
Comorbidities				
COPD	0.663	0.065	0.844	0.791
Diabetes	↑<0.001	↑0.028	↑0.009	↑0.010
TB-related Characteristics				
Extrapulmonary TB (n=8380)	↑<0.001	0.060	↑0.022	↑0.005
Positive AFB Smear (n=7683)	↑<0.001	↑<0.001	↑<0.001	0.179
DR-TB	↑<0.001	↑<0.001	↑<0.001	↑0.002
No. of Contacts (n=8103)	↑0.017	↑0.007	0.910	0.090
All adverse treatment Outcomes				
Treatment Failure	0.976	0.318	0.539	0.525
Abandoned Treatment	↓<0.001	↓0.003	↓0.028	0.789
Died	0.278	↓0.004	0.934	0.283

Note: n indicated in parenthesis for variables with missing data. DR-TB= resistant to any of the TB drugs tested (i.e. isoniazid, rifampin, pyrazinamide, streptomycin, ethambutol)

^a p values shown for the score test for trend of odds for categorical variables, and for the nonparametric test for trend across ordered groups, for number of contacts

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values